www.fdanews.com/articles/126280-sanofi-reaches-more-settlements-on-release-of-generic-eloxatin
Sanofi Reaches More Settlements on Release of Generic Eloxatin
April 16, 2010
Sanofi-Aventis has reached settlement
agreements with Hospira, Par Pharmaceutical and Actavis that would allow the generic companies to join three others in introducing generic versions of
Sanofi’s Eloxatin colorectal cancer drug in 2012. The pay-for-delay agreements — which must be approved
by the FTC, Justice Department and the Michigan state attorney general — require the generic drugmakers to stop selling generic Eloxatin (oxaliplatin)
June 30 and allow them to resume sales Aug. 9, 2012, under a license from Sanofi, the French drugmaker said.
Generic Line
Generic Line